In the past, there have been many studies on the predictive analysis of the prognosis of CRC [4], and most research focuses on the traditional clinicopathological indicators (such as tumor size, tumor count, lymph node metastasis, vascular invasion, etc.)or single tumor-specific biomarkers (such as carcinoembryonic antigen CEA, carbohydrate antigen-CA199, etc.)[5–7]. This evidence concerns the gene CEACAM5 and neoplasm.